Education
About Us
Working with TipRanks
Follow Us
Jagsonpal Pharmaceuticals Ltd. (IN:JAGSNPHARM)
:JAGSNPHARM
Total Valuation
Jagsonpal Pharmaceuticals Ltd. has a market cap or net worth of ₹14.80B. The enterprise value is ―.
Market Cap₹14.80B
Enterprise Value―
Share Statistics
Jagsonpal Pharmaceuticals Ltd. has 66,724,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding66,724,700
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Jagsonpal Pharmaceuticals Ltd.’s return on equity (ROE) is 0.23 and return on invested capital (ROIC) is 13.59%.
Return on Equity (ROE)0.23
Return on Assets (ROA)0.20
Return on Invested Capital (ROIC)13.59%
Return on Capital Employed (ROCE)0.17
Revenue Per Employee2.62M
Profits Per Employee540.11K
Employee Count1,025
Asset Turnover0.97
Inventory Turnover6.34
Valuation Ratios
The current PE Ratio of Jagsonpal Pharmaceuticals Ltd. is 24.2. Jagsonpal Pharmaceuticals Ltd.’s PEG ratio is 0.18.
PE Ratio24.2
PS Ratio5.44
PB Ratio6.09
Price to Fair Value6.09
Price to FCF26.60
Price to Operating Cash Flow0.00
PEG Ratio0.18
Income Statement
In the last 12 months, Jagsonpal Pharmaceuticals Ltd. had revenue of 2.69B and earned 553.61M in profits. Earnings per share was 8.26.
Revenue2.69B
Gross Profit1.72B
Operating Income435.49M
Pretax Income698.59M
Net Income553.61M
EBITDA510.71M
Earnings Per Share (EPS)8.26
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Jagsonpal Pharmaceuticals Ltd. pays an annual dividend of ₹2.5, resulting in a dividend yield of 1.13%
Dividend Per Share₹2.5
Dividend Yield1.13%
Payout Ratio33.63%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.19
52-Week Price Change23.14%
50-Day Moving Average232.76
200-Day Moving Average229.82
Relative Strength Index (RSI)44.69
Average Volume (3m)10.11K
Important Dates
Jagsonpal Pharmaceuticals Ltd. upcoming earnings date is Nov 18, 2025, TBA (Confirmed).
Last Earnings DateJul 26, 2025
Next Earnings DateNov 18, 2025
Ex-Dividend DateSep 12, 2025
Financial Position
Jagsonpal Pharmaceuticals Ltd. as a current ratio of 6.22, with Debt / Equity ratio of 0.00%
Current Ratio6.22
Quick Ratio5.64
Debt to Market Cap0.00
Net Debt to EBITDA-2.34
Interest Coverage Ratio45.46
Taxes
In the past 12 months, Jagsonpal Pharmaceuticals Ltd. has paid 144.98M in taxes.
Income Tax144.98M
Effective Tax Rate0.21
Enterprise Valuation
Jagsonpal Pharmaceuticals Ltd. EV to EBITDA ratio is 26.28, with an EV/FCF ratio of 24.43.
EV to Sales5.00
EV to EBITDA26.28
EV to Free Cash Flow24.43
EV to Operating Cash Flow24.27
Balance Sheet
Jagsonpal Pharmaceuticals Ltd. has ₹1.29B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of ₹1.29B billion.
Cash & Marketable Securities₹1.29B
Total Debt₹0.00
Net Cash₹1.29B
Net Cash Per Share₹19.29
Tangible Book Value Per Share₹22.92
Margins
Gross margin is 56.64%, with operating margin of 16.21%, and net profit margin of 20.60%.
Gross Margin56.64%
Operating Margin16.21%
Pretax Margin26.00%
Net Profit Margin20.60%
EBITDA Margin19.01%
EBIT Margin15.98%
Analyst Forecast
The average price target for Jagsonpal Pharmaceuticals Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast34.72%
EPS Growth Forecast196.94%